No Data
No Data
Baolitianheng (688506.SH): Zhu Yi accumulated shareholding of 0.05 million shares.
On July 23, Gelunhui reported that as of July 22, 2024, Mr. Zhu Yi acquired a total of 50,520 shares of the company through the Shanghai Stock Exchange trading system in a centralized bidding trading method, accounting for 0.01% of the company's total share capital. The total shareholding amount was RMB 8.2821 million (excluding stamp duty, transaction commission and other transaction costs), and the shareholding plan implementation was completed.
Bailitianheng (688506.SH): Injection use of BL-M14D1 (ADC) project for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notice.
On July 11th, Gelunhui reported that Baili Tianheng (688506.SH) recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA). The clinical trial of the company's independently developed innovative biological drug BL-M14D1 (ADC) has been approved. BL-M14D1 is an ADC drug that shares the same "linker + toxin" platform as BL-B01D1, both of which are derived from the same small molecule technology platform. Its indication is late-stage solid tumors.
Sichuan Biokin Pharmaceutical Submits Hong Kong IPO Application
Bailey Tianheng (688506.SH) has submitted an application for the listing of H shares to the Stock Exchange of Hong Kong.
Bailitianheng (688506.SH) announced that the company is applying for a public offering of overseas listed stocks (H shares) and ...
Biokin Pharmaceutical Enrolls First Patient in Breast Cancer Drug Trial
Bailitanheng (688506.SH): The first subject was enrolled in the phase III clinical trial of BL-B01D1 for locally advanced or metastatic triple-negative breast cancer.
On July 3rd, Gelunhui reported that Bailitianheng (688506.SH) announced that the Phase III clinical trial of BL-B01D1 (EGFR×HER3-ADC) injection, an innovative biological drug independently developed and used alone for unresectable locally advanced or metastatic triple-negative breast cancer that has failed previously treated with taxanes, has completed the first subject enrollment. So far, BL-B01D1 monotherapy has been registered for Phase III clinical trials in domestic terminal nasopharyngeal carcinoma, line 2 esophageal squamous cell carcinoma, HR+HER2- breast cancer, EGFR mutation type non-small cell lung cancer, and EGFR wild-type non-small cell lung cancer.
No Data